Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics

Natalia Lelental, Sebastian Brandner, Olga Kofanova, Kaj Blennow, Henrik Zetterberg, Ulf Andreasson, Sebastiaan Engelborghs, Barbara Mroczko, Tomasz Gabryelewicz, Charlotte Teunissen, Brit Mollenhauer, Lucilla Parnetti, Davide Chiasserini, Jose Luis Molinuevo, Armand Perret-Liaudet, Marcel M. Verbeek, Niels Andreasen, Frederic Brosseron, Justyna M.C. Bahl, Sanna Kaisa HerukkaLucrezia Hausner, Lutz Frölich, Anne Labonte, Judes Poirier, Anne Marie Miller, Norbert Zilka, Branislav Kovacech, Andrea Urbani, Silvia Suardi, Catarina Oliveira, Ines Baldeiras, Bruno Dubois, Uros Rot, Sylvain Lehmann, Anders Skinningsrud, Fay Betsou, Jens Wiltfang, Olymbia Gkatzima, Bengt Winblad, Michael Buchfelder, Johannes Kornhuber, Piotr Lewczuk*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)


Background: Assay-vendor independent quality control (QC) samples for neurochemical dementia diagnostics (NDD) biomarkers are so far commercially unavailable. This requires that NDD laboratories prepare their own QC samples, for example by pooling leftover cerebrospinal fluid (CSF) samples. Objective: To prepare and test alternative matrices for QC samples that could facilitate intra- and inter-laboratory QC of the NDD biomarkers. Methods: Three matrices were validated in this study: (A) human pooled CSF, (B) Aβ peptides spiked into human prediluted plasma, and (C) Aβ peptides spiked into solution of bovine serum albumin in phosphate-buffered saline. All matrices were tested also after supplementation with an antibacterial agent (sodium azide). We analyzed short- and long-term stability of the biomarkers with ELISA and chemiluminescence (Fujirebio Europe, MSD, IBL International), and performed an inter-laboratory variability study. Results: NDD biomarkers turned out to be stable in almost all samples stored at the tested conditions for up to 14 days as well as in samples stored deep-frozen (at - 80°C) for up to one year. Sodium azide did not influence biomarker stability. Inter-center variability of the samples sent at room temperature (pooled CSF, freeze-dried CSF, and four artificial matrices) was comparable to the results obtained on deep-frozen samples in other large-scale projects. Conclusion: Our results suggest that it is possible to replace self-made, CSF-based QC samples with large-scale volumes of QC materials prepared with artificial peptides and matrices. This would greatly facilitate intra- and inter-laboratory QC schedules for NDD measurements.

Original languageEnglish
Pages (from-to)51-64
Number of pages14
JournalJournal of Alzheimer's Disease
Issue number1
Publication statusPublished - 26 Apr 2016


  • Alzheimer's disease
  • amyloid-β
  • biomarkers
  • cerebrospinal fluid
  • laboratory diagnostics
  • quality control
  • tau


Dive into the research topics of 'Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics'. Together they form a unique fingerprint.

Cite this